RU2070408C1 - Средство, уменьшающее мышечную регидность, и средство для лечения болезни паркинсона - Google Patents

Средство, уменьшающее мышечную регидность, и средство для лечения болезни паркинсона Download PDF

Info

Publication number
RU2070408C1
RU2070408C1 SU915001150A SU5001150A RU2070408C1 RU 2070408 C1 RU2070408 C1 RU 2070408C1 SU 915001150 A SU915001150 A SU 915001150A SU 5001150 A SU5001150 A SU 5001150A RU 2070408 C1 RU2070408 C1 RU 2070408C1
Authority
RU
Russia
Prior art keywords
acid
flupirtine
agent
esters
parkinson
Prior art date
Application number
SU915001150A
Other languages
English (en)
Russian (ru)
Inventor
Лобиш Михаэль
Венхауз Ральф
Никель Бернд
Сцелении Истван
Энгель Юрген
Эмиг Петер
Original Assignee
Аста Медика Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аста Медика Аг filed Critical Аста Медика Аг
Application granted granted Critical
Publication of RU2070408C1 publication Critical patent/RU2070408C1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Details Of Television Scanning (AREA)
  • Paints Or Removers (AREA)
  • Golf Clubs (AREA)
SU915001150A 1990-07-14 1991-07-12 Средство, уменьшающее мышечную регидность, и средство для лечения болезни паркинсона RU2070408C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
DEP4022442.2 1990-07-14
IN421CA1991 IN172468B (enExample) 1990-07-14 1991-06-04

Publications (1)

Publication Number Publication Date
RU2070408C1 true RU2070408C1 (ru) 1996-12-20

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
SU915001150A RU2070408C1 (ru) 1990-07-14 1991-07-12 Средство, уменьшающее мышечную регидность, и средство для лечения болезни паркинсона

Country Status (30)

Country Link
US (2) US5162346A (enExample)
EP (2) EP0659410B1 (enExample)
KR (1) KR0182811B1 (enExample)
CN (1) CN1070700C (enExample)
AT (2) ATE206919T1 (enExample)
AU (1) AU634073B2 (enExample)
CA (1) CA2046943C (enExample)
CZ (1) CZ280879B6 (enExample)
DE (3) DE59109222D1 (enExample)
DK (2) DK0659410T3 (enExample)
EG (1) EG19814A (enExample)
ES (2) ES2164111T3 (enExample)
GR (1) GR3019179T3 (enExample)
HR (1) HRP920667B1 (enExample)
HU (1) HU206973B (enExample)
IE (1) IE74688B1 (enExample)
IL (1) IL98810A (enExample)
IN (1) IN172468B (enExample)
LT (1) LT3593B (enExample)
LV (1) LV10048B (enExample)
MC (1) MC2272A1 (enExample)
MX (1) MX9100160A (enExample)
NO (1) NO912758L (enExample)
NZ (1) NZ238940A (enExample)
PT (1) PT98291B (enExample)
RO (1) RO108220B1 (enExample)
RU (1) RU2070408C1 (enExample)
SI (1) SI9111227B (enExample)
SK (1) SK279567B6 (enExample)
ZA (1) ZA915466B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000303A1 (en) * 2002-06-24 2003-12-31 Obschestvo S Ogranichennoi Otvetstvennostiu 'parkinfarm' Method for therapeutic modality on a patient organism during the cure of parkinson's disease

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2111659T3 (es) * 1992-03-11 1998-03-16 Asta Medica Ag Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion.
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
HUP0301296A2 (hu) * 1999-08-03 2003-08-28 Awd.Pharma Gmbh & Co. Kg Flupirtin alkalmazása degeneratív ízületi fájdalom kezelésére
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) * 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
BRPI0607017B8 (pt) 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
EP2012769A1 (en) * 2006-05-02 2009-01-14 Rundfeldt, Chris Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
NZ575652A (en) * 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) * 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US20100256145A1 (en) * 2007-08-01 2010-10-07 H. Lundbeck A/S Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
JP2022553569A (ja) 2019-11-08 2022-12-23 ゼノン・ファーマシューティカルズ・インコーポレイテッド うつ病性障害の治療方法
WO2022173855A1 (en) 2021-02-09 2022-08-18 Xenon Pharmaceuticals Inc. Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
DE3665538D1 (en) * 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
ATE43789T1 (de) * 1985-02-23 1989-06-15 Asta Pharma Ag Kombination von flupirtin und anticholinergisch wirkenden spasmolytika.
DE3604575A1 (de) * 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
FI855016A7 (fi) * 1985-06-28 1986-12-29 Degussa Flupirtiinin ja 4-asetamido-fenolin synergistinen yhdistelmä.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Машковский М.Д. Лекарственные средства. Т.1.- 1986, с.265. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000303A1 (en) * 2002-06-24 2003-12-31 Obschestvo S Ogranichennoi Otvetstvennostiu 'parkinfarm' Method for therapeutic modality on a patient organism during the cure of parkinson's disease

Also Published As

Publication number Publication date
CN1058716A (zh) 1992-02-19
PT98291A (pt) 1992-05-29
SI9111227A (en) 1995-06-30
DK0659410T3 (da) 2001-12-27
RO108220B1 (ro) 1994-03-31
ATE206919T1 (de) 2001-11-15
EG19814A (en) 1996-02-29
DK0467164T3 (da) 1996-03-04
IL98810A0 (en) 1992-07-15
MC2272A1 (fr) 1993-06-23
HRP920667B1 (en) 1998-06-30
ES2082887T3 (es) 1996-04-01
EP0467164A2 (de) 1992-01-22
EP0467164A3 (en) 1992-04-15
SK279567B6 (sk) 1999-01-11
LTIP919A (en) 1995-03-27
IE74688B1 (en) 1997-07-30
MX9100160A (es) 1992-02-28
HU206973B (en) 1993-03-01
ZA915466B (en) 1992-04-29
LT3593B (en) 1995-12-27
DE59107331D1 (de) 1996-03-14
PT98291B (pt) 1999-01-29
GR3019179T3 (en) 1996-06-30
IL98810A (en) 1996-01-19
US5162346A (en) 1992-11-10
HRP920667A2 (en) 1996-10-31
DE59109222D1 (de) 2001-11-22
ES2164111T3 (es) 2002-02-16
CS210191A3 (en) 1992-02-19
CA2046943C (en) 1996-03-12
IE912451A1 (en) 1992-01-15
LV10048A (lv) 1994-05-10
CN1070700C (zh) 2001-09-12
CA2046943A1 (en) 1992-01-15
HUT59313A (en) 1992-05-28
AU634073B2 (en) 1993-02-11
LV10048B (en) 1995-06-20
EP0659410A2 (de) 1995-06-28
CZ280879B6 (cs) 1996-04-17
NO912758D0 (no) 1991-07-12
NZ238940A (en) 1997-05-26
US5284861A (en) 1994-02-08
EP0659410B1 (de) 2001-10-17
DE4122166A1 (de) 1992-01-16
KR920002147A (ko) 1992-02-28
SI9111227B (sl) 2000-12-31
EP0659410A3 (de) 1995-10-25
HU912359D0 (en) 1991-12-30
ATE133564T1 (de) 1996-02-15
IN172468B (enExample) 1993-08-14
EP0467164B1 (de) 1996-01-31
AU8040391A (en) 1992-01-16
KR0182811B1 (ko) 1999-05-01
NO912758L (no) 1992-01-15

Similar Documents

Publication Publication Date Title
RU2070408C1 (ru) Средство, уменьшающее мышечную регидность, и средство для лечения болезни паркинсона
RU2621615C2 (ru) Фармацевтическая композиция, содержащая луликоназол
JP2991733B2 (ja) 乾癬疾患を抑制するための薬剤及びその製法
JPH0460973B2 (enExample)
JPH11512115A (ja) 経口投与用製剤組成物
CA2444103C (en) Composition for treating drug-induced constipation with 15-keto-prostaglandins
CN101410097A (zh) 软明胶胶囊制剂
KR101817028B1 (ko) 지속성 케토프로펜 조성물
US6562868B1 (en) Method for treatment of female sexual dysfunction
JP5427029B2 (ja) 消化管の重炭酸分泌を促進するための方法および組成物
US11771706B2 (en) Oral solutions comprising fludrocortisone acetate
JP3048602B2 (ja) ポリプレニル系化合物を含有する医薬組成物およびその製造方法
FR2773489A1 (fr) Nouvelle composition destinee a la voie oromuqueuse notamment pernasale
EP3932390A1 (en) Topical gel formulation containing asimadoline
EP1455774B1 (en) Pharmaceutical composition for treating obesity
JP2827245B2 (ja) 鎮痛剤
CA2022081C (en) Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
JPH05117141A (ja) 副腎エキス含有消炎鎮痛ゲル剤
WO2020188457A1 (en) Solutions for oral dosage
NZ232059A (en) Compositions and use of an alkyl glycerine and azelastine: (4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1h-azepine-4-yl)-1(2h)-phthalazinone; preparatory processes
JPS6256133B2 (enExample)